SAN DIEGO, Dec. 5, 2016 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage oncology drug development company, announces the expansion of the Company's MVT-5873 phase I clinical trial to include the HonorHealth Research Institute located in Scottsdale, Arizona. HonorHealth Research Institute is a premier research organization focused on improving the health and well-being of patients. HonorHealth Research Institute focuses on transitional medicine bridging new cancer treatments from research into clinical development. HonorHealth Research Institute joins Memorial Sloan Kettering Cancer Center site in New York, and the Sarah Cannon Research Institute sites in Nashville, Tennessee and, Sarasota, Florida as phase I clinical trial sites for MabVax's fully human therapeutic antibody therapy.
The phase I trial is evaluating the safety, tolerability and pharmacokinetics of MVT-5873 as a single agent or in combination with a current standard-of-care chemotherapy regimen in patients with metastatic pancreatic cancer. The first part of the clinical trial is enrolling patients in a traditional dose escalation regimen to assess safety and determine the recommended phase 2 dose (RP2D) of the antibody. The second part of the clinical trial is enrolling patients to establish the safety and RP2D of MVT-5873 when administered with a standard-of-care chemotherapy. The lead investigator for the clinical trial at HonorHealth Research Institute is Erkut Borazanci, MD, MS.
"HonorHealth is involved in treating the first individuals with advanced pancreatic cancer with nab-paclitaxel plus gemcitabine and nanoliposomal irinotecan and 5-Fluorouraci," said Erkut Borazanci, MD, a medical oncologist at the HonorHealth Research Institute. "We have seen tremendous progress in treating pancreatic cancer by using the best scientific insights and bringing them directly to patients. We are excited to be partnering with MabVax Therapeutics on such an important clinical trial."
"We are very excited to engage with HonorHealth's world-class clinical research organization and are looking forward to drawing upon the organization's extensive expertise in the development of new therapeutic agents particularly for patients with advanced pancreatic cancer," said David Hansen, MabVax President and CEO. "The addition of HonorHealth Research Institute comes as we are expanding our phase I trial to treat patients newly diagnosed with pancreatic cancer with MVT-5873 in combination with chemotherapy. Pancreatic cancer is very difficult to treat and patients with advanced disease have few therapeutic options. We are delighted to be working with researchers at HonorHealth to evaluate MVT-5873 as a potential new therapeutic option for these patients."
Patients seeking information about this research study may contact the HonorHealth Research Institute at 480-323-1339 or toll free at 1-877-273-3713, or email [email protected].
About HonorHealth Research Institute:
HonorHealth Research Institute is a unique hybrid of world-class care and groundbreaking clinical trials and research. Leading researchers, physicians and clinical teams work together to bring newly discovered therapies and diagnostic products, as well as provide innovative care and treatments to patients. Through the offerings of its strategic partnerships, the Institute is able to make the greatest impact on the patients' health and quality of life, by bringing tomorrow's cures that offer hope to patients today.
About HonorHealth:
HonorHealth is a non-profit health system serving an area of 1.6 million people in the greater Phoenix area. The company encompasses five acute-care hospitals, an extensive medical group, outpatient surgery centers, a cancer center, clinical research, medical education, a foundation and community services with approximately 11,500 employees, 3,700 affiliated physicians and 3,100 volunteers. HonorHealth was formed by a merger between Scottsdale Healthcare and John C. Lincoln Health Network. HonorHealth's mission is to improve the health and well-being of those we serve. Learn more at HonorHealth.com.
About MVT-5873:
MabVax's MVT-5873 is a fully human antibody discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine during a Phase I trial at Memorial Sloan Kettering Cancer Center. In preclinical research, the antibody has demonstrated high specificity and affinity, and has shown potent cancer cell killing capacity and efficacy in animal models of pancreatic, colon and small cell lung cancers. The antigen the antibody targets is expressed on more than 90% of pancreatic cancers making the antibody potentially broadly applicable to most patients suffering from this type of cancer.
About MabVax:
MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers with the Company's proprietary vaccines. MabVax also has the exclusive license to the therapeutic vaccines from Memorial Sloan Kettering Cancer Center. Additional information is available at www.mabvax.com.
Forward Looking Statements:
This press release contains "forward-looking statements" regarding matters that are not historical facts, including statements relating to the Company's clinical trials of MVT-5873 both as a standalone study as well as in combination with a standard of care chemotherapy. We have no assurance that MVT-5873 will be fully developed by the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the fiscal year ended December 31, 2015, as amended and supplemented from time to time and the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. The parties do not undertake any obligation to update forward-looking statements contained in this press release.
Investor Contact:
Robert Haag Managing DirectorIRTH [email protected] 1-866-976-4784
HonorHealth Contact:Alice GiedraitisMedia Relations [email protected]
Advertisement
The phase I trial is evaluating the safety, tolerability and pharmacokinetics of MVT-5873 as a single agent or in combination with a current standard-of-care chemotherapy regimen in patients with metastatic pancreatic cancer. The first part of the clinical trial is enrolling patients in a traditional dose escalation regimen to assess safety and determine the recommended phase 2 dose (RP2D) of the antibody. The second part of the clinical trial is enrolling patients to establish the safety and RP2D of MVT-5873 when administered with a standard-of-care chemotherapy. The lead investigator for the clinical trial at HonorHealth Research Institute is Erkut Borazanci, MD, MS.
Advertisement
"HonorHealth is involved in treating the first individuals with advanced pancreatic cancer with nab-paclitaxel plus gemcitabine and nanoliposomal irinotecan and 5-Fluorouraci," said Erkut Borazanci, MD, a medical oncologist at the HonorHealth Research Institute. "We have seen tremendous progress in treating pancreatic cancer by using the best scientific insights and bringing them directly to patients. We are excited to be partnering with MabVax Therapeutics on such an important clinical trial."
"We are very excited to engage with HonorHealth's world-class clinical research organization and are looking forward to drawing upon the organization's extensive expertise in the development of new therapeutic agents particularly for patients with advanced pancreatic cancer," said David Hansen, MabVax President and CEO. "The addition of HonorHealth Research Institute comes as we are expanding our phase I trial to treat patients newly diagnosed with pancreatic cancer with MVT-5873 in combination with chemotherapy. Pancreatic cancer is very difficult to treat and patients with advanced disease have few therapeutic options. We are delighted to be working with researchers at HonorHealth to evaluate MVT-5873 as a potential new therapeutic option for these patients."
Patients seeking information about this research study may contact the HonorHealth Research Institute at 480-323-1339 or toll free at 1-877-273-3713, or email [email protected].
About HonorHealth Research Institute:
HonorHealth Research Institute is a unique hybrid of world-class care and groundbreaking clinical trials and research. Leading researchers, physicians and clinical teams work together to bring newly discovered therapies and diagnostic products, as well as provide innovative care and treatments to patients. Through the offerings of its strategic partnerships, the Institute is able to make the greatest impact on the patients' health and quality of life, by bringing tomorrow's cures that offer hope to patients today.
About HonorHealth:
HonorHealth is a non-profit health system serving an area of 1.6 million people in the greater Phoenix area. The company encompasses five acute-care hospitals, an extensive medical group, outpatient surgery centers, a cancer center, clinical research, medical education, a foundation and community services with approximately 11,500 employees, 3,700 affiliated physicians and 3,100 volunteers. HonorHealth was formed by a merger between Scottsdale Healthcare and John C. Lincoln Health Network. HonorHealth's mission is to improve the health and well-being of those we serve. Learn more at HonorHealth.com.
About MVT-5873:
MabVax's MVT-5873 is a fully human antibody discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine during a Phase I trial at Memorial Sloan Kettering Cancer Center. In preclinical research, the antibody has demonstrated high specificity and affinity, and has shown potent cancer cell killing capacity and efficacy in animal models of pancreatic, colon and small cell lung cancers. The antigen the antibody targets is expressed on more than 90% of pancreatic cancers making the antibody potentially broadly applicable to most patients suffering from this type of cancer.
About MabVax:
MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers with the Company's proprietary vaccines. MabVax also has the exclusive license to the therapeutic vaccines from Memorial Sloan Kettering Cancer Center. Additional information is available at www.mabvax.com.
Forward Looking Statements:
This press release contains "forward-looking statements" regarding matters that are not historical facts, including statements relating to the Company's clinical trials of MVT-5873 both as a standalone study as well as in combination with a standard of care chemotherapy. We have no assurance that MVT-5873 will be fully developed by the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the fiscal year ended December 31, 2015, as amended and supplemented from time to time and the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. The parties do not undertake any obligation to update forward-looking statements contained in this press release.
Investor Contact:
Robert Haag Managing DirectorIRTH [email protected] 1-866-976-4784
HonorHealth Contact:Alice GiedraitisMedia Relations [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mabvax-therapeutics-expands-phase-i-clinical-trial-investigation-for-patients-with-pancreatic-cancer-to-include-honorhealth-research-institute-300372602.html
SOURCE MabVax Therapeutics Holdings, Inc.
